Pediatrics high grade gliomas (pHGGs) are the most frequent pediatric brain tumor with poor prognosis. Currently, standard-of-care (SOC) treatments cannot completely eradicate the tumor and do not significantly increase the patient survival rate. Accordingly, there is an unmet need to develop new therapeutic strategies against pHGGs. Recently, oncolytic virus (OV) treatment has provided a new immunotherapy direction for cancer therapy, which acts by both direct lysis of tumor cells and by activating the host anti-tumor immune response.
Augusta University Research Institute, Inc.
1120 15th Street
Augusta, GA 30912
United StatesThe Augusta University Research Institute (AURI) Inc. was established in 1981 as a separately incorporated 501(c) 3 to serve AU by enhancing its mission of excellence in research, teaching, and service.
AURI serves as the applicant and awardee institution for most sponsored proposals developed by AU's faculty. AURI is supported by the pre-award and post-award staff of the Division of Sponsored Program Administration. As each project is funded, AURI enters into a subcontract with AU for the performance of the work. Sponsor payments are received by AURI and paid to AU. AURI retains a portion of the Facilities and Administrative costs paid by sponsors to support its operations and to fund reinvestment programs.